{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:32:29Z","timestamp":1792265549489,"version":"4.4.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11390-6","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:26:50Z","timestamp":1766982410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Myostatin inhibitors in sarcopenia treatment: A comprehensive review of mechanisms, efficacy and future directions"],"prefix":"10.1007","volume":"53","author":[{"given":"Sahar Ahmad","family":"Samali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyede Fatemeh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"11390_CR1","doi-asserted-by":"crossref","unstructured":"Cho MR, Lee S, Song SK (2022) A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. J Korean Med Sci 37(18)","DOI":"10.3346\/jkms.2022.37.e146"},{"issue":"1","key":"11390_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16\u201331","journal-title":"Age Ageing"},{"issue":"3","key":"11390_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","volume":"21","author":"LK Chen","year":"2020","unstructured":"Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S (2020) Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21(3):300\u2013307","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"11390_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s11010-024-05120-y","volume":"480","author":"B Wetzlich","year":"2025","unstructured":"Wetzlich B, Nyakundi BB, Yang J (2025) Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions. Mol Cell Biochem 480(3):1535\u20131553","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"11390_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.afos.2023.03.008","volume":"9","author":"A Mitra","year":"2023","unstructured":"Mitra A, Qaisar R, Bose B, Sudheer SP (2023) The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis. Osteoporos Sarcopenia 9(1):1\u20137","journal-title":"Osteoporos Sarcopenia"},{"issue":"7","key":"11390_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00018-022-04408-w","volume":"79","author":"E Abati","year":"2022","unstructured":"Abati E, Manini A, Comi GP, Corti S (2022) Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases. Cell Mol Life Sci 79(7):374","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"11390_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11005\/jbm.2020.27.3.151","volume":"27","author":"J Suh","year":"2020","unstructured":"Suh J, Lee YS (2020) Myostatin inhibitors: panacea or predicament for musculoskeletal disorders? J Bone Metab 27(3):151","journal-title":"J Bone Metab"},{"key":"11390_CR8","doi-asserted-by":"publisher","first-page":"876078","DOI":"10.3389\/fphys.2022.876078","volume":"13","author":"MH Baig","year":"2022","unstructured":"Baig MH, Ahmad K, Moon JS, Park SY, Ho Lim J, Chun HJ, Qadri AF, Hwang YC, Jan AT, Ahmad SS (2022) Myostatin and its regulation: a comprehensive review of myostatin inhibiting strategies. Front Physiol 13:876078","journal-title":"Front Physiol"},{"issue":"8","key":"11390_CR9","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/cells10082070","volume":"10","author":"P Esposito","year":"2021","unstructured":"Esposito P, Verzola D, Picciotto D, Cipriani L, Viazzi F, Garibotto G (2021) Myostatin\/activin-A signaling in the vessel wall and vascular calcification. Cells 10(8):2070","journal-title":"Cells"},{"issue":"21","key":"11390_CR10","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.3390\/ijms21217940","volume":"21","author":"TM Mirzoev","year":"2020","unstructured":"Mirzoev TM (2020) Skeletal muscle recovery from disuse atrophy: protein turnover signaling and strategies for accelerating muscle regrowth. Int J Mol Sci 21(21):7940","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11390_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1210\/endrev\/bnab030","volume":"43","author":"BD Rodgers","year":"2022","unstructured":"Rodgers BD, Ward CW (2022) Myostatin\/activin receptor ligands in muscle and the development status of attenuating drugs. Endocr Rev 43(2):329\u2013365","journal-title":"Endocr Rev"},{"issue":"1","key":"11390_CR12","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1038\/s41467-018-05439-3","volume":"9","author":"SJ Lessard","year":"2018","unstructured":"Lessard SJ, MacDonald TL, Pathak P, Han MS, Coffey VG, Edge J, Rivas DA, Hirshman MF, Davis RJ, Goodyear LJ (2018) JNK regulates muscle remodeling via myostatin\/SMAD inhibition. Nat Commun 9(1):3030","journal-title":"Nat Commun"},{"issue":"2","key":"11390_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/genes16020153","volume":"16","author":"LHS Fagundes","year":"2025","unstructured":"Fagundes LHS, Pimenta EM, Costa VT (2025) Effects of physical exercise on MuRF-1\/TRIM63 mRNA expression in humans: a systematic review. Genes 16(2):153","journal-title":"Genes"},{"issue":"1","key":"11390_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s10020-024-00981-x","volume":"30","author":"XQ Shan","year":"2024","unstructured":"Shan XQ, Zhou N, Pei CX, Lu X, Chen CP, Chen HQ (2024) Tetrandrine induces muscle atrophy involving ROS-mediated inhibition of Akt and FoxO3. Mol Med 30(1):218","journal-title":"Mol Med"},{"issue":"4","key":"11390_CR15","first-page":"1619","volume":"15","author":"AR Sharma","year":"2024","unstructured":"Sharma AR, Chatterjee S, Lee YH, Lee SS (2024) Targeting crosstalk of signaling pathways among Muscles-Bone-Adipose tissue: A promising therapeutic approach for sarcopenia. Aging Disease 15(4):1619","journal-title":"Aging Disease"},{"key":"11390_CR16","doi-asserted-by":"crossref","unstructured":"Lan XQ, Deng CJ, Wang QQ, Zhao LM, Jiao BW, Xiang Y (2024) The role of TGF-\u03b2 signaling in muscle atrophy, sarcopenia and cancer cachexia. Gen Comp Endocrinol:114513","DOI":"10.1016\/j.ygcen.2024.114513"},{"key":"11390_CR17","doi-asserted-by":"crossref","unstructured":"Hoogaars WM, Jaspers RT (2018) Past, present, and future perspective of targeting myostatin and related signaling pathways to counteract muscle atrophy. Muscle Atrophy 153\u2013206","DOI":"10.1007\/978-981-13-1435-3_8"},{"issue":"4","key":"11390_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.5455\/javar.2022.i625","volume":"9","author":"CD Gaina","year":"2022","unstructured":"Gaina CD, Amalo FA (2022) Genetic polymorphism of myostatin gene in Sumba Ongole (Bos indicus) cattle and its association with growth traits. J Adv Vet Anim Res 9(4):565","journal-title":"J Adv Vet Anim Res"},{"issue":"11","key":"11390_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3390\/genes13112055","volume":"13","author":"M Kruszewski","year":"2022","unstructured":"Kruszewski M, Aksenov MO (2022) Association of myostatin gene polymorphisms with strength and muscle mass in athletes: a systematic review and meta-analysis of the MSTN Rs1805086 mutation. Genes 13(11):2055","journal-title":"Genes"},{"key":"11390_CR20","doi-asserted-by":"publisher","first-page":"144400","DOI":"10.1016\/j.gene.2020.144400","volume":"740","author":"IL Haruna","year":"2020","unstructured":"Haruna IL, Ekegbu UJ, Ullah F, Amirpour-Najafabadi H, Zhou H, Hickford JG (2020) Genetic variations and haplotypic diversity in the Myostatin gene of New Zealand cattle breeds. Gene 740:144400","journal-title":"Gene"},{"issue":"3","key":"11390_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1152\/ajpendo.00216.2016","volume":"312","author":"T Kocsis","year":"2017","unstructured":"Kocsis T, Trencsenyi G, Szabo K, Baan JA, Muller G, Mendler L, Garai I, Reinauer H, Deak F, Dux L (2017) Myostatin propeptide mutation of the hypermuscular Compact mice decreases the formation of myostatin and improves insulin sensitivity. American Journal of Physiology-Endocrinology and Metabolism 312(3):150\u2013160","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"5","key":"11390_CR22","doi-asserted-by":"publisher","first-page":"e97399","DOI":"10.1371\/journal.pone.0097399","volume":"9","author":"C Bouyer","year":"2014","unstructured":"Bouyer C, Forestier L, Renand G, Oulmouden A (2014) Deep intronic mutation and pseudo exon activation as a novel muscular hypertrophy modifier in cattle. PLoS One 9(5):e97399","journal-title":"PLoS One"},{"issue":"10","key":"11390_CR23","doi-asserted-by":"publisher","first-page":"0205664","DOI":"10.1371\/journal.pone.0205664","volume":"13","author":"MF Rooney","year":"2018","unstructured":"Rooney MF, Hill EW, Kelly VP, Porter RK (2018) The speed gene effect of myostatin arises in Thoroughbred horses due to a promoter proximal SINE insertion. PLoS ONE 13(10):0205664","journal-title":"PLoS ONE"},{"issue":"1","key":"11390_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/1471-2164-11-552","volume":"11","author":"EW Hill","year":"2010","unstructured":"Hill EW, McGivney BA, Gu J, Whiston R, MacHugh DE (2010) A genome-wide SNP-association study confirms a sequence variant (g. 66493737C\u2009>\u2009T) in the equine myostatin (MSTN) gene as the most powerful predictor of optimum racing distance for thoroughbred racehorses. BMC Genomics 11(1):552","journal-title":"BMC Genomics"},{"key":"11390_CR25","doi-asserted-by":"crossref","unstructured":"Hill EW, Fonseca RG, McGivney BA, Gu J, MacHugh DE, Katz LM (2012) MSTN genotype (g. 66493737C\/T) association with speed indices in Thoroughbred racehorses. J Appl Physiol 112(1):86\u201390","DOI":"10.1152\/japplphysiol.00793.2011"},{"issue":"1","key":"11390_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4314\/njb.v39i1.3","volume":"39","author":"B Ilori","year":"2022","unstructured":"Ilori B, Isong S, Oghate E, Ojeniyi B, Durosaro S, Akano K, Oguntade D, Onakoya B, Olapade S, Ozoje M (2022) Evaluation of Single Nucleotide Polymorphism and Genetic Diversity at the Myostatin gene Locus in Indigenous and Locally Adapted Exotic Turkey breeds in Nigeria. Nigerian J Biotechnol 39(1):20\u201330","journal-title":"Nigerian J Biotechnol"},{"issue":"1","key":"11390_CR27","doi-asserted-by":"publisher","first-page":"7916","DOI":"10.1038\/s41598-021-86783-1","volume":"11","author":"V O\u2019Hara","year":"2021","unstructured":"O\u2019Hara V, Cowan A, Riddell D, Massey C, Martin J, Piercy RJ (2021) A highly prevalent SINE mutation in the myostatin (MSTN) gene promoter is associated with low Circulating myostatin concentration in thoroughbred racehorses. Sci Rep 11(1):7916","journal-title":"Sci Rep"},{"issue":"1","key":"11390_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12863-014-0119-2","volume":"15","author":"S Bongiorni","year":"2014","unstructured":"Bongiorni S, Tilesi F, Bicorgna S, Iacoponi F, Willems D, Gargani M, D\u2019Andrea M, Pilla F, Valentini A (2014) Promoter polymorphisms in genes involved in porcine myogenesis influence their transcriptional activity. BMC Genet 15(1):119","journal-title":"BMC Genet"},{"issue":"9","key":"11390_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/02640414.2013.865252","volume":"32","author":"X Li","year":"2014","unstructured":"Li X, Wang S-J, Tan SC, Chew PL, Liu L, Wang L, Wen L, Ma L (2014) The A55T and K153R polymorphisms of MSTN gene are associated with the strength training-induced muscle hypertrophy among Han Chinese men. J Sports Sci 32(9):883\u2013891","journal-title":"J Sports Sci"},{"issue":"13","key":"11390_CR30","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.3390\/ijerph17134900","volume":"17","author":"J Kim","year":"2020","unstructured":"Kim J, Park K, Lee J (2020) Myostatin A55T genotype is associated with strength recovery following exercise-induced muscle damage. International Journal of Environmental Research and Public Health 17(13):4900","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"11390_CR31","doi-asserted-by":"crossref","unstructured":"Szl\u00e1ma G, Trexler M, Buday L, Patthy L (2015) K153R polymorphism in myostatin gene increases the rate of promyostatin activation by furin. FEBS letters 589(3):295\u2013301","DOI":"10.1016\/j.febslet.2014.12.011"},{"issue":"8","key":"11390_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1046\/j.1532-5415.2001.49214.x","volume":"49","author":"MJ Seibert","year":"2001","unstructured":"Seibert MJ, Xue QL, Fried LP, Walston JD (2001) Polymorphic variation in the human myostatin (GDF-8) gene and association with strength measures in the Women\u2019s Health and Aging Study II cohort. Journal of the American Geriatrics Society 49(8):1093\u20136","journal-title":"Journal of the American Geriatrics Society"},{"key":"11390_CR33","doi-asserted-by":"crossref","unstructured":"Dilger A, Chen X, Honegger L, Marron B, Beever J (2022) The potential for gene-editing to increase muscle growth in pigs: experiences with editing myostatin. CABI Agriculture and Bioscience 3(1):36","DOI":"10.1186\/s43170-022-00106-6"},{"issue":"2","key":"11390_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/jcsm.12937","volume":"13","author":"L Gonz\u00e1lez-Blanco","year":"2022","unstructured":"Gonz\u00e1lez-Blanco L, Berm\u00fadez M, Bermejo\u2010Millo JC, Guti\u00e9rrez\u2010Rodr\u00edguez J, Solano JJ, Antu\u00f1a E, Men\u00e9ndez\u2010Valle I, Caballero B, Vega\u2010Naredo I, Potes Y (2022) Cell interactome in sarcopenia during aging. J Cachexia Sarcopenia Muscle 13(2):919\u2013931","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"11390_CR35","doi-asserted-by":"crossref","unstructured":"Lim C, Nunes EA, Currier BS, Mcleod JC, Thomas AC, Phillips SM (2022) an evidence-based narrative review of mechanisms of resistance exercise\u2013induced human skeletal muscle hypertrophy. Med Sci Sports Exerc 54(9):1546","DOI":"10.1249\/MSS.0000000000002929"},{"key":"11390_CR36","doi-asserted-by":"crossref","unstructured":"Graham ZA, Lavin KM, O\u2019Bryan SM, Thalacker-Mercer AE, Buford TW, Ford KM, Broderick TJ, Bamman MM (2021) mechanisms of exercise as a preventative measure to muscle wasting. Am J Physiology-Cell Physiol 321(7):40\u201357","DOI":"10.1152\/ajpcell.00056.2021"},{"key":"11390_CR37","doi-asserted-by":"crossref","unstructured":"Jang J, Park S, Kim Y, Jung J, Lee J, Chang Y, Lee SP, Park B-C, Wolfe RR, Choi CS (2021) myostatin inhibition-induced increase in muscle mass and strength was amplified by resistance exercise training, and dietary essential amino acids improved muscle quality in mice. Nutrients 13(5):1508","DOI":"10.3390\/nu13051508"},{"key":"11390_CR38","doi-asserted-by":"crossref","unstructured":"Millward DJ (2021) Interactions between growth of muscle and stature: mechanisms involved and their nutritional sensitivity to dietary protein: the protein-stat revisited. Nutrients 13(3):729","DOI":"10.3390\/nu13030729"},{"key":"11390_CR39","doi-asserted-by":"crossref","unstructured":"Gharahdaghi N, Phillips BE, Szewczyk NJ, Smith K, Wilkinson DJ, Atherton PJ (2021) links between testosterone, oestrogen, and the growth hormone\/insulin-like growth factor axis and resistance exercise muscle adaptations. Front Physiol 11:621226","DOI":"10.3389\/fphys.2020.621226"},{"key":"11390_CR40","doi-asserted-by":"crossref","unstructured":"Sartori R, Romanello V, Sandri M (2021) Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nature communications 12(1):330","DOI":"10.1038\/s41467-020-20123-1"},{"key":"11390_CR41","doi-asserted-by":"crossref","unstructured":"Latres E, Pangilinan J, Miloscio L, Bauerlein R, Na E, Potocky TB, Huang Y, Eckersdorff M, Rafique A Mastaitis(s) (2015) Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle 5:1\u201313","DOI":"10.1186\/s13395-015-0060-8"},{"key":"11390_CR42","doi-asserted-by":"crossref","unstructured":"Wetzlich B, Nyakundi BB, Yang J (2024) Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions. Molecular and Cellular Biochemistry 1\u201319","DOI":"10.1007\/s11010-024-05120-y"},{"key":"11390_CR43","doi-asserted-by":"crossref","unstructured":"Kablar B, Krastel K, Tajbakhsh S, Rudnicki MA (2003) Myf5 and myod activation define independent myogenic compartments during embryonic development. Dev Biol 258(2):307\u2013318","DOI":"10.1016\/S0012-1606(03)00139-8"},{"key":"11390_CR44","doi-asserted-by":"crossref","unstructured":"Muntoni F, Byrne BJ, McMillan HJ, Ryan MM, Wong BL, Dukart J, Bansal A, Cosson V, Dreghici R, Guridi M, Rabbia M, Staunton H, Tirucherai GS, Yen K, Yuan X, Wagner KR, Taldefgrobep Alfa Study G (2024) the clinical development of Taldefgrobep alfa: an anti-Myostatin adnectin for the treatment of Duchenne muscular dystrophy. Neurol Ther 13(1):183\u2013219","DOI":"10.1007\/s40120-023-00570-w"},{"key":"11390_CR45","doi-asserted-by":"crossref","unstructured":"Wagner K, Wong B, Byrne B, Sweeney H, Jacobsen L, Tirucherai G, Rabbia M, Dukart J, Kletz H, Krishnan M (2018) DMD CLINICAL THERAPIES I: P. 123A randomized, placebo-controlled, double-blind, phase 1b\/2 study of the novel anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy. Neuromuscular Disorders 28(S66","DOI":"10.1212\/WNL.90.15_supplement.P5.431"},{"issue":"6","key":"11390_CR46","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3390\/biomedicines11061635","volume":"11","author":"JY Jang","year":"2023","unstructured":"Jang JY, Kim D, Kim ND (2023) Pathogenesis, intervention, and current status of drug development for sarcopenia: a review. Biomedicines 11(6):1635","journal-title":"Biomedicines"},{"key":"11390_CR47","doi-asserted-by":"crossref","unstructured":"Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI (2008) A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy. Annals of neurology 63(5):561\u2013571","DOI":"10.1002\/ana.21338"},{"key":"11390_CR48","doi-asserted-by":"crossref","unstructured":"Sherlock SP, Palmer J, Wagner KR, Abdel-Hamid HZ, Bertini E, Tian C, Mah JK, Kostera-Pruszczyk A, Muntoni, Guglieri FM (2022) quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of Domagrozumab. J Neurol 269(8):4421\u20134435","DOI":"10.1007\/s00415-022-11084-0"},{"key":"11390_CR49","doi-asserted-by":"crossref","unstructured":"Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, Hochberg MC, Ferrari SL, Blain H, Binder EF (2015) myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 3(12):948\u2013957","DOI":"10.1016\/S2213-8587(15)00298-3"},{"key":"11390_CR50","doi-asserted-by":"crossref","unstructured":"Register ECT (2020) Trevogrumab (REGN1033) Phase 2 Trial in Older Adults at Risk of Mobility Disability. EudraCT 2013-003134-33. (Accessed 27 January 2025 https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003134-33\/results?utm_source=chatgpt.com . (Accessed 27 January 2025","DOI":"10.7748\/ns2013.03.27.27.33.p10687"},{"key":"11390_CR51","doi-asserted-by":"crossref","unstructured":"Crawford TO, Darras BT, Day JW, Dunaway Young S, Duong T, Nelson LL, Barrett D, Song G, Bilic, Cote SS (2024) safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study. Neurology 102(5):209151","DOI":"10.1212\/WNL.0000000000209151"},{"key":"11390_CR52","doi-asserted-by":"crossref","unstructured":"Welsh BT, Cote SM, Meshulam D, Jackson J, Pal A, Lansita J, Kalra A (2021) Preclinical safety assessment and toxicokinetics of apitegromab, an antibody targeting proforms of myostatin for the treatment of muscle-atrophying disease. International Journal of Toxicology 40(4):322\u2013336","DOI":"10.1177\/10915818211025477"},{"key":"11390_CR53","doi-asserted-by":"crossref","unstructured":"Vainshtein A, Sandri M (2020) Signaling pathways that control muscle mass. International journal of molecular sciences 21(13):4759","DOI":"10.3390\/ijms21134759"},{"key":"11390_CR54","doi-asserted-by":"crossref","unstructured":"Muntoni F, Byrne BJ, McMillan HJ, Ryan MM, Wong BL, Dukart J, Bansal A, Cosson V, Dreghici R Guridi(s) (2024) The clinical development of taldefgrobep alfa: An anti-myostatin adnectin for the treatment of Duchenne muscular dystrophy. Neurol Therapy 13(1):183\u2013219","DOI":"10.1007\/s40120-023-00570-w"},{"key":"11390_CR55","doi-asserted-by":"crossref","unstructured":"Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA (2018) AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight 3(22):123538","DOI":"10.1172\/jci.insight.123538"},{"issue":"1","key":"11390_CR56","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","volume":"23","author":"JR Mendell","year":"2015","unstructured":"Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S (2015) A phase 1\/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther 23(1):192\u2013201","journal-title":"Mol Ther"},{"issue":"3","key":"11390_CR57","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/156652312800840577","volume":"12","author":"H Amthor","year":"2012","unstructured":"Amthor H, Hoogaars MH (2012) Interference with myostatin\/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Curr Gene Ther 12(3):245\u2013259","journal-title":"Curr Gene Ther"},{"issue":"3","key":"11390_CR58","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3803\/EnM.2021.1081","volume":"36","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Kwon KS (2021) Receptor-mediated muscle homeostasis as a target for sarcopenia therapeutics. Endocrinol Metab 36(3):478\u2013490","journal-title":"Endocrinol Metab"},{"issue":"6","key":"11390_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1515\/jbcpp-2024-0065","volume":"35","author":"M Kaur","year":"2024","unstructured":"Kaur M, Misra S (2024) Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity. J Basic Clin Physiol Pharmacol 35(6):325\u2013334","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"10","key":"11390_CR60","doi-asserted-by":"publisher","first-page":"e2020836","DOI":"10.1001\/jamanetworkopen.2020.20836","volume":"3","author":"D Rooks","year":"2020","unstructured":"Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N, Coleman LA, Miller RR, Garayoa EG, Praestgaard J (2020) Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw open 3(10):e2020836\u2013e2020836","journal-title":"JAMA Netw open"},{"issue":"4","key":"11390_CR61","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F (2014) An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 34(4):606\u2013618","journal-title":"Mol Cell Biol"},{"key":"11390_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101880","volume":"80","author":"E Nunn","year":"2024","unstructured":"Nunn E, Jaiswal N, Gavin M, Uehara K, Stefkovich M, Drareni K, Calhoun R, Lee M, Holman CD, Baur JA (2024) Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular Metabolism 80:101880","journal-title":"Molecular Metabolism"},{"issue":"1","key":"11390_CR63","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1152\/ajpcell.00142.2010","volume":"300","author":"DL Allen","year":"2011","unstructured":"Allen DL, Loh AS (2011) Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. Am J Physiology-Cell Physiol 300(1):124\u2013137","journal-title":"Am J Physiology-Cell Physiol"},{"key":"11390_CR64","doi-asserted-by":"crossref","unstructured":"Chen MM, Zhao YP, Zhao Y, Deng SL, Yu K Yu(s) (2021) Regulation of myostatin on the growth and development of skeletal muscle. Front cell Dev biology 9:785712","DOI":"10.3389\/fcell.2021.785712"},{"key":"11390_CR65","doi-asserted-by":"crossref","unstructured":"R\u0131\u0301os R, Carneiro I, Arce VM, Devesa J (2002) Myostatin is an inhibitor of myogenic differentiation. American Journal of Physiology-Cell Physiology 282(5):993-999","DOI":"10.1152\/ajpcell.00372.2001"},{"issue":"24","key":"11390_CR66","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1158\/0008-5472.CAN-14-0057","volume":"74","author":"YS Gallot","year":"2014","unstructured":"Gallot YS, Durieux A-C, Castells J, Desgeorges MM, Vernus B, Plantureux L, R\u00e9mond D, Jahnke VE, Lefai E, Dardevet D (2014) Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res 74(24):7344\u20137356","journal-title":"Cancer Res"},{"issue":"12","key":"11390_CR67","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.biocel.2010.09.017","volume":"42","author":"Y Chen","year":"2010","unstructured":"Chen Y, Ye J, Cao L, Zhang Y, Xia W, Zhu D (2010) Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells. The international journal of biochemistry & cell biology 42(12):2072\u20132081","journal-title":"The international journal of biochemistry & cell biology"},{"issue":"6","key":"11390_CR68","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1152\/ajpcell.00105.2009","volume":"296","author":"AU Trendelenburg","year":"2009","unstructured":"Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ (2009) Myostatin reduces Akt\/TORC1\/p70S6K signaling, inhibiting myoblast differentiation and myotube size. American Journal of Physiology-Cell Physiology 296(6):1258\u20131270","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"10","key":"11390_CR69","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.3390\/ijms19103125","volume":"19","author":"DM Thomson","year":"2018","unstructured":"Thomson DM (2018) The role of AMPK in the regulation of skeletal muscle size, hypertrophy, and regeneration. International journal of molecular sciences 19(10):3125","journal-title":"International journal of molecular sciences"},{"key":"11390_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","volume":"2","author":"Y Elkina","year":"2011","unstructured":"Elkina Y, von Haehling S, Anker SD, Springer J (2011) The role of myostatin in muscle wasting: an overview. Journal of cachexia, sarcopenia and muscle 2:143\u2013151","journal-title":"Journal of cachexia, sarcopenia and muscle"},{"key":"11390_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2021.01.030","volume":"543","author":"SJ Lee","year":"2021","unstructured":"Lee SJ, Gharbi A, Shin JE, Jung ID, Park YM (2021) Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. Biochem Biophys Res Commun 543:1\u20137","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"11390_CR72","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41598-021-81222-7","volume":"11","author":"W Eilers","year":"2021","unstructured":"Eilers W, Cleasby M, Foster K (2021) Development of antisense-mediated myostatin knockdown for the treatment of insulin resistance. Scientific Reports 11(1):1604","journal-title":"Scientific Reports"},{"key":"11390_CR73","doi-asserted-by":"crossref","unstructured":"Tinklenberg JA, Siebers EM, Beatka MJ, Meng H, Yang L, Zhang Z, Ross JA, Ochala J, Morris C, Owens JM Myostatin inhibition using mRK35 produces skeletal muscle growth and tubular aggregate formation in wild type and Tg ACTA1 D286G nemaline myopathy mice. Hum Mol Genet 27(4):638\u2013648","DOI":"10.1093\/hmg\/ddx431"},{"issue":"1","key":"11390_CR74","doi-asserted-by":"publisher","first-page":"9878","DOI":"10.1038\/s41598-017-10404-z","volume":"7","author":"C Wallner","year":"2017","unstructured":"Wallner C, Jaurich H, Wagner JM, Becerikli M, Harati K, Dadras M, Lehnhardt M, Behr B (2017) Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Sci Rep 7(1):9878","journal-title":"Sci Rep"},{"issue":"24","key":"11390_CR75","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1093\/hmg\/ddt342","volume":"22","author":"LR Rodino-Klapac","year":"2013","unstructured":"Rodino-Klapac LR, Janssen PM, Shontz KM, Canan B, Montgomery CL, Griffin D, Heller K, Schmelzer L, Handy C, Clark(s) KR (2013) Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet 22(24):4929\u20134937","journal-title":"Hum Mol Genet"},{"issue":"7","key":"11390_CR76","doi-asserted-by":"publisher","first-page":"e68743","DOI":"10.1371\/journal.pone.0068743","volume":"8","author":"MG MacKenzie","year":"2013","unstructured":"MacKenzie MG, Hamilton DL, Pepin M, Patton A, Baar K (2013) Inhibition of myostatin signaling through Notch activation following acute resistance exercise. PLoS ONE 8(7):e68743","journal-title":"PLoS ONE"},{"issue":"5","key":"11390_CR77","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mus.27684","volume":"66","author":"D Vargas-Franco","year":"2022","unstructured":"Vargas-Franco D, Kalra R, Draper I, Pacak CA, Asakura A, Kang PB (2022) The Notch signaling pathway in skeletal muscle health and disease. Muscle Nerve 66(5):530\u2013544","journal-title":"Muscle Nerve"},{"issue":"19","key":"11390_CR78","doi-asserted-by":"publisher","first-page":"10273","DOI":"10.3390\/ijms251910273","volume":"25","author":"L Servais","year":"2024","unstructured":"Servais L, Lair LL, Connolly AM, Byrne BJ, Chen KS, Coric V, Qureshi I, Durham S, Campbell DJ, Maclaine G (2024) Taldefgrobep Alfa and the phase 3 RESILIENT trial in spinal muscular atrophy. Int J Mol Sci 25(19):10273","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11390_CR79","doi-asserted-by":"publisher","first-page":"893","DOI":"10.14336\/AD.2023.0713-1","volume":"15","author":"R Schellino","year":"2024","unstructured":"Schellino R, Boido M, Vrijbloed JW, Fariello RG, Vercelli A (2024) Synergistically acting on myostatin and agrin pathways increases neuromuscular junction stability and endurance in old mice. Aging and Disease 15(2):893","journal-title":"Aging and Disease"},{"issue":"6","key":"11390_CR80","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1007\/s12325-021-01757-z","volume":"38","author":"D Barrett","year":"2021","unstructured":"Barrett D, Bilic S, Chyung Y, Cote SM, Iarrobino R, Kacena K, Kalra A, Long K, Nomikos G, Place A (2021) A randomized phase 1 safety, Pharmacokinetic and pharmacodynamic study of the novel myostatin inhibitor apitegromab (SRK-015): a potential treatment for spinal muscular atrophy. Adv Therapy 38(6):3203\u20133222","journal-title":"Adv Therapy"},{"issue":"2","key":"11390_CR81","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.27259","volume":"64","author":"DG Leung","year":"2021","unstructured":"Leung DG, Bocchieri AE, Ahlawat S, Jacobs MA, Parekh VS, Braverman V, Summerton K, Mansour J, Stinson N, Bibat G (2021) A phase Ib\/IIa, open-label, multiple ascending-dose trial of Domagrozumab in fukutin-related protein limb-girdle muscular dystrophy. Muscle Nerve 64(2):172\u2013179","journal-title":"Muscle Nerve"},{"issue":"4","key":"11390_CR82","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM (2017) myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55(4):458\u2013464","journal-title":"Muscle Nerve"},{"issue":"1","key":"11390_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mus.21200","volume":"39","author":"LS Krivickas","year":"2009","unstructured":"Krivickas LS, Walsh R, Amato(s AA (2009) Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 39(1):3\u20139","journal-title":"Muscle Nerve"},{"issue":"1","key":"11390_CR84","doi-asserted-by":"publisher","first-page":"2033457","DOI":"10.1001\/jamanetworkopen","volume":"4","author":"S Heymsfield","year":"2021","unstructured":"Heymsfield S, Coleman L, Miller R, Rooks D, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry R (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open 4(1):2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen","journal-title":"JAMA Netw Open"},{"issue":"4","key":"11390_CR85","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/SPC.0000000000000013","volume":"7","author":"RC Smith","year":"2013","unstructured":"Smith RC, Lin(s BK (2013) Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care 7(4):352\u2013360","journal-title":"Curr Opin Support Palliat Care"},{"issue":"50","key":"11390_CR86","first-page":"50","volume":"20","author":"KR Wagner","year":"2019","unstructured":"Wagner KR, Wong BL, Byrne BJ, Tian C, Jacobsen LK, Tirucherai GS, Rabbia M, Kletzl H, Ong R, Yen K (2019) A phase 1b\/2 study of the anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy (DMD): A 72-week treatment update. Age 20(50):50","journal-title":"Age"},{"issue":"9","key":"11390_CR87","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jgs.14927","volume":"65","author":"D Rooks","year":"2017","unstructured":"Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R (2017) Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc 65(9):1988\u20131995","journal-title":"J Am Geriatr Soc"},{"key":"11390_CR88","volume-title":"Inhibition of Myostatin for the Prevention and Treatment of Cardiac Dysfunction after Aortic Constriction","author":"PA Quintero","year":"2010","unstructured":"Quintero PA, Coggins M, Xiao C, Rosenzweig A (2010) Inhibition of Myostatin for the Prevention and Treatment of Cardiac Dysfunction after Aortic Constriction. Lippincott Williams & Wilkins"},{"issue":"1","key":"11390_CR89","first-page":"32","volume":"78","author":"S-J Lee","year":"2023","unstructured":"Lee S-J, Bhasin S, Klickstein L, Krishnan V, Rooks D (2023) Challenges and future prospects of targeting myostatin\/activin A signaling to treat diseases of muscle loss and metabolic dysfunction. The Journals of Gerontology: Series A 78(1):32\u201337","journal-title":"The Journals of Gerontology: Series A"},{"issue":"12","key":"11390_CR90","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41417-020-0178-7","volume":"27","author":"S Weng","year":"2020","unstructured":"Weng S, Gao F, Wang J, Li X, Chu B, Wang J, Yang G (2020) Improvement of muscular atrophy by AAV\u2013SaCas9-mediated myostatin gene editing in aged mice. Cancer Gene Therapy 27(12):960\u2013975","journal-title":"Cancer Gene Therapy"},{"issue":"1","key":"11390_CR91","doi-asserted-by":"publisher","first-page":"10568","DOI":"10.1038\/s41598-025-95115-6","volume":"15","author":"M Oura","year":"2025","unstructured":"Oura M, Son B-K, Song Z, Toyoshima K, Nanao-Hamai M, Ogawa S, Akishita M (2025) Testosterone\/androgen receptor antagonizes immobility-induced muscle atrophy through Inhibition of myostatin transcription and inflammation in mice. Sci Rep 15(1):10568","journal-title":"Sci Rep"},{"key":"11390_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150892","volume":"736","author":"H Go","year":"2024","unstructured":"Go H, Sung NJ, Choi J, Kim L, Park EJ (2024) 6\u2032-sialyllactose prevents dexamethasone-induced muscle atrophy by controlling the muscle protein degradation pathway. Biochemical and Biophysical Research Communications 736:150892","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"11390_CR93","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/biomedicines13020352","volume":"13","author":"CC Tsai","year":"2025","unstructured":"Tsai CC, Wang PC, Hsiung T, Fan YH, Wu JT, Kan WC, Shiao CC (2025) sarcopenia in chronic kidney disease: A narrative review from pathophysiology to therapeutic approaches. Biomedicines 13(2):352","journal-title":"Biomedicines"},{"issue":"1","key":"11390_CR94","doi-asserted-by":"publisher","first-page":"13691","DOI":"10.1002\/jcsm.13691","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Xu J, Yao S, Zhang N, Zhang BT, Zhang ZK (2025) Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches. Journal of Cachexia, Sarcopenia and Muscle 16(1):13691","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"issue":"3","key":"11390_CR95","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1371\/journal.pone.0004937","volume":"4","author":"T Guo","year":"2009","unstructured":"Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC (2009) Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PloS one 4(3):4937","journal-title":"PloS one"},{"issue":"1","key":"11390_CR96","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","volume":"20","author":"SJ Lee","year":"2004","unstructured":"Lee SJ (2004) Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20(1):61\u201386","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"11390_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156057","volume":"161","author":"K Stefanakis","year":"2024","unstructured":"Stefanakis K, Kokkorakis M, Mantzoros CS (2024) The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 161:156057","journal-title":"Metabolism"},{"issue":"1","key":"11390_CR98","doi-asserted-by":"publisher","first-page":"17535","DOI":"10.1038\/srep17535","volume":"5","author":"PV Sepulveda","year":"2015","unstructured":"Sepulveda PV, Lamon S, Hagg A, Thomson RE, Winbanks CE, Qian H, Bruce CR, Russell AP, Gregorevic P (2015) evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy. Sci Rep 5(1):17535","journal-title":"Sci Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11390-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:02:19Z","timestamp":1766988139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11390-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11390"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11390-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"224"}}